Using serum samples collected from the PsiDeR trial—a randomised, double‑blind, placebo‑controlled study of a single 25 mg dose of psilocybin for treatment‑resistant depression (protocol: BMJ Open 2021;11:e056091)—we will investigate whether inflammatory marker trajectories and baseline inflammatory status are associated with antidepressant response at week 3 (endpoint). The inflammatory...
Research SquareJuly 9, 2026Samuel Westenhöfer, Yamina Ehrt, Barbora Provaznikova et al.
preprint
Abstract Background : Treatment-resistant depression (TRD) is associated with substantial clinical and socioeconomic burden. Intranasal esketamine has shown efficacy for TRD in clinical trials and real-world studies. However, evidence on optimal maintenance scheduling is limited. We therefore investigated whether two maintenance schedules differing in their inter-dose intervals were associated...
Intravenous ketamine is used for treatment-resistant depression, with structured guidelines supporting its use, but requires careful patient monitoring due to potential side effects and variable efficacy.
Frontiers in PsychiatryJuly 9, 2026Patrice A. Bellanti, Jordan Lewis, Brian Seifferth et al.
Introduction Intravenous (IV) ketamine and intranasal esketamine are NMDA receptor antagonists used for treatment-resistant depression (TRD). Both have demonstrated efficacy in controlled trials, but observational evidence from real-world community settings is limited. Methods We conducted a single-center retrospective cohort study of adults aged 18 to 65 receiving induction therapy for TRD...
Abstract Background: Online Mindfulness-Based Cognitive Therapy (MBCT) offers a scalable approach to treating depression, yet high attrition and sustained engagement remain persistent challenges, particularly for individuals with active symptoms. This convergent mixed-methods study aimed to explore how individuals with current depressive symptoms experience and navigate digital mindfulness...
Major depressive disorder (MDD) is a heterogeneous mental disorder characterised by rumination. Mindfulness-based cognitive therapy (MBCT) is an evidence-based treatment developed to target rumination and recurrence risk. Ongoing studies have begun to identify neural changes associated with treatment effects. However, the low-dimensional organisation underlying whole-brain dynamics remains...
BACKGROUND: -dimethyltryptamine (DMT); however, long-term effects, including broader well-being dimensions, are sparsely explored across populations. AIMS: Investigating whether DMT produces sustained improvements in anxiety, life satisfaction, and quality of life, in both healthy individuals and patients with treatment-resistant depression (TRD). METHODS: In 2 open-label clinical trials, 27...
Few topics in contemporary psychiatry generate as much fascination, hope, and discomfort as the therapeutic use of psychedelics.For some, they represent a long-awaited disruption in the treatment of depression, a field in which many patients still experience partial response, relapse, or treatment resistance despite decades of
Introduction: While the rapid and robust effects of ketamine on depressive symptoms in treatment-resistant depression (TRD) have been demonstrated, the influence of ketamine treatment on cognitive function has not yet been fully elucidated. We aimed to evaluate the effects of ketamine treatment on cognitive function as part of a study that investigated the efficacy of repeated ketamine...